Utilization and outcomes of nutrient-stimulated hormone therapies in patients undergoing bariatric surgery.

Authors

Claudia R Villatoro Santos, Hector D Estrada Tock, Haoran Tang, Laura N McEwen, Andrew Kraftson, William H Herman, Amy E Rothberg

Published in

International journal of obesity (2005). Jul 20, 2026. Epub Jul 20, 2026.

Abstract

To describe the impact of nutrient-stimulated hormone (NuSH) therapies on weight loss by bariatric surgery type, diabetes status, and timing of initial NuSH prescription.
Retrospective study of 1638 adults who underwent bariatric surgery at a single academic medical center between 2015 and 2022. Baseline demographics, NuSH therapy prescriptions, and follow-up weights were obtained from electronic health records. We calculated percent total weight loss (%TWL) over time using linear mixed models.
Patients who underwent Roux-en-Y gastric bypass (RYGB) had greater %TWL compared to those who underwent sleeve gastrectomy (SG). Those without diabetes had greater %TWL compared to those with diabetes. At 72 months, adjusted average %TWL was highest in patients who received NuSH prescriptions both before and after surgery (22.7%, 95% CI: 17.9-27.5), followed by those with prescriptions only after surgery (19.9%, 95% CI: 18.3-21.4) and those without prescriptions (19.6%, 95% CI: 18.1-21.2). The greatest %TWL was seen in patients who had prescriptions within 6 months after surgery.
Individuals who underwent RYGB and who did not have diabetes had the highest %TWL. Receiving a NuSH prescription both before and after surgery and early NuSH initiation were associated with the greatest %TWL.

PMID:
42477476
Bibliographic data and abstract were imported from PubMed on 21 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.